Abraxane

For example, Abraxane is being tested along with Avastin, a treatment from Genentech that costs $8,000 a month for some patients.

Democracy's Vices, Arnold Kling | EconLog | Library of Economics and Liberty 2009

And, in at least one way, Abraxane is a breakthrough: it costs about 25 times as much as a generic version of the older medicine, which is best known by its brand name, Taxol.

Democracy's Vices, Arnold Kling | EconLog | Library of Economics and Liberty 2009

But Abraxane is fairly priced, he said, because it is based on a scientific breakthrough that the company refers to as “nanoparticle technology.”

Democracy's Vices, Arnold Kling | EconLog | Library of Economics and Liberty 2009

Medicare, which pays for Abraxane, is also forbidden by law from considering cost in deciding what treatments to cover.

Democracy's Vices, Arnold Kling | EconLog | Library of Economics and Liberty 2009

The deal is part of an effort to expand beyond its strength in blood cancer treatments by increasing its presence overseas and pushing into treating other cancers with Abraxane, which is a form of chemotherapy.

Celgene Profit Drops 16% as Revenue Jumps Thomas Gryta 2011

The deal gives Celgene the opportunity to become a bigger presence in oncology care, with the addition of Abraxane, which is approved to treat breast cancer in the US, and has the potential to treat other cancers such as non-small cell lung cancer and pancreatic cancer.

Celgene Flexes Muscle With Abraxis Buy 2010

Dr. Link favors a regimen that combines Avastin with a chemotherapy drug from Abraxis Bioscience Inc. called Abraxane, a newer version of the approved drug Taxol.

Pricey Drugs Put Squeeze on Doctors 2008

That new drug is called Abraxane and it has pushed Abraxis BioScience stock from $5 in 2002 to $27 in 2007.

Did Abraxis BioScience instruct AstraZeneca to use illegal marketing in their quest to increase sales? 2007

Since then, the FDA has approved dozens of biologics for a wide range of uses, such as Abraxane, a chemical wrapped in human proteins, for breast cancer.

John Horton: Biologics: Are Unsafe Drugs an 'Acceptable Risk?' FDA Should Say 'No!' John Horton 2010

Earlier this month, Celgene disclosed that Abraxane didn't show statistical significance in expanding progression-free survival in lung cancer in interim results of a clinical trial.

Celgene Profit Drops 16% as Revenue Jumps Thomas Gryta 2011